Single-Dose, Randomized, Open-Label, Two-Way, Crossover Bioequivalence Study of Two Formulations of Pregabalin 300 mg Hard Capsules in Healthy Volunteers Under Fasting Conditions
Augusto Filipe, Susana Almeida, Pedro Filipe Pedroso, Rita Neves, Susana Marques, Eric Sicard, Julie Massicotte, Jordi Ortuño, Augusto Filipe, Susana Almeida, Pedro Filipe Pedroso, Rita Neves, Susana Marques, Eric Sicard, Julie Massicotte, Jordi Ortuño
Abstract
Aims: This bioequivalence study was conducted to assess the bioequivalence of two formulations, test and reference, of pregabalin 300 mg hard capsules, under fasting conditions.
Methods: This was a single-center, randomized, single-dose, open-label, laboratory-blinded, two-way crossover study, with a minimum washout period of 7 days. Plasma samples were collected prior to and up to 36 h after dosing. Pregabalin plasma concentrations were determined, using a validated method, by reversed phase high performance liquid chromatography coupled to a tandem mass spectrometry detector (LC-MS-MS). Pharmacokinetic metrics used for bioequivalence assessment were the AUC(0-t) (area under the plasma concentration-time curve from time zero to time of last observed non-zero plasma concentration) and the C max (maximum observed plasma concentration). These parameters were determined from the pregabalin plasma concentration data using noncompartmental analysis.
Results: Forty healthy subjects, age ranging from 18 to 43 years old, were enrolled and randomized, of whom 39 completed the study. The ratio of geometric least square means for C max was 99.29 % (90 % confidence interval [CI] 93.29-105.67). The ratio of geometric least square means for AUC(0-t) was 101.54 % (90 % CI 100.13-102.98). The 90 % CIs were within the predefined range (80.00-125.00).
Conclusions: Bioequivalence between test and reference formulations, under fasting conditions, was concluded both in terms of rate and extent of absorption.
Figures
References
- Lyseng-Williamson K, Siddiqui M. Pregabalin: a review of its use in fibromyalgia. Drugs. 2008;65(15):2202–2223.
- Lyrica® [Label] (23/12/2013). NDA 021446, Drugs@FDA. . Accessed 23 Aug 2014.
- European Medicines Agency. Lyrica: EPAR—Product Information . Accessed 23 Oct 2014.
- Shoji S, Misaki S, Tomamo Y, Bookbrader HN, Matsui S. Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia on diabetic peripheral neuropathy. Br J Clin Pharmacol. 2011;72(1):63–76. doi: 10.1111/j.1365-2125.2011.03932.x.
- European Medicines Agency. Committee for Medicinal products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. CPMO/EWP/QWP/1401/98 Rev. 1 20 Jan 2010.
- Declaration of Helsinki. World Medical Association Declaration of Hensinki, adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and last amended by the 64th General Assembly, Fortaleza, Brazil, October 2013. . Accessed 23 Oct 2014.
- International Conference on Harmonization. Guideline for Good Clinical Practice (ICH E6).
- Quiñones L, Sasso J, Tamayo E, Catalán J, González JP, Escala M, Varela N, León J, Cáceres DD, Saavedra I. A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. Ther Adv Chronic Dis. 2010;1(4):141–148. doi: 10.1177/2040622310379932.
- Al-Ghazawi A, Idkaidek N, Daccache E, Sarraf JC, Kyriacos S. Bioequivalence of two pregabalin 300 mg capsules (Neurexal and Lyrica®) in healthy human volunteers. Drug Res (Stuttg) 2014;64(7):358–362.
- Cook J, Addicks W, Wu YW. Application of the Biopharmaceutical Classification System in clinical drug development—an industrial view. AAPS J. 2008;10(2):306–310. doi: 10.1208/s12248-008-9036-5.
Source: PubMed